The outcome for patients with unresectable/metastatic soft tissue sarcoma 
remains poor with few treatment options. In the first line setting, a number of 
randomized trials have shown no difference in overall survival between 
combination anthracycline schedules and single agent doxorubicin. A Phase 
Ib/randomized Phase II trial of doxorubicin with or without the monoclonal 
antibody to PDGFR-α, olaratumab, demonstrated a significant difference in median 
overall survival in favor of the olaratumab arm. The results of this trial led 
to approval of olaratumab in combination with doxorubicin in adult 
anthracycline-naive unresectable soft tissue sarcoma. In this review, we 
describe some of the preclinical and early clinical data of olaratumab in 
sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas.